Nutraceutix acquires exclusive rights to
drug delivery patent
25 Sep 2001
Nutraceutix Inc., has acquired a license for pharmaceutical applications for the first CDT Controlled
Delivery Technology patent from
Temple University School of Pharmacy, Philadelphia.
This new U.S. license
grants exclusive rights to develop, manufacture and sell prescription oral dosage forms of
drugs, as well as OTC products, and
dietary supplements as previously licensed to Nutraceutix. Developed in the
laboratories of Dr. Reza Fassihi, Ph.D., at Temple, the second CDT patent (U.S. pat. No. 6,090,411) was licensed
exclusively to Nutraceutix in September 2000 for pharmaceutical, OTC, and nutraceutical applications.
The platform of CDT technologies may signal a milestone in delivery technology science as they address many of
the challenges common to delivery systems that are currently available. The new technology has been shown to
be rugged and robust during in-vitro studies on a wide range of established
pharmaceuticals, such as nifedipine,
theophylline, propanolol,
diltiazem, and
verapamil, as well as OTC and
nutritional supplements such as
pseudoephedrine,
glucosamine and niacin.
According to David T. Howard, president & CEO of Nutraceutix Inc., "The U.S. patent for pharmaceutical
applications provides Nutraceutix with a clear technological advantage over first generation, controlled delivery
systems. Now, complementing our existing alliances with OTC and nutraceutical companies, we will seek to
partner with major pharmaceutical and generic companies as well, to co-develop new
prescription drugs
incorporating Nutraceutix's technology."
The underlying technical principles of the developed technologies are sound.
drug delivery and the system can be
optimally manipulated to meet many of the challenges of the next decade that we face in life- cycle
management of both old and new drugs. Formulation flexibility of the developed systems lends itself to easy
production of a larger range of dose variants for elderly patients and individualized dosage regimens.